secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001558370-23-009248
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA Q1 net loss $19.7M; cash $110M; milestones from Roche and Gilead; Phase 2 data on track for Q2 2023
--------------------------------------------------------------------------------

- Q1 net loss $19.7M vs $18.0M YoY; revenue $3.2M (up from $1.4M) on higher collaboration recognition.
- Cash $110.0M at March 31, 2023, down from $113.4M at Dec 31, 2022; used in operations partly offset by collaboration funds.
- Achieved $10M milestone from Roche for HB-700 (KRAS-mutated cancers) and $5M from Gilead for HB-400 (chronic hepatitis B).
- Phase 2 data for HB-200 in HPV16+ head and neck cancer with pembrolizumab expected in Q2 2023; Phase 1 trials initiated for HB-300 and HB-400.
- Appointed Terry Coelho to Board of Directors; preclinical data presented at AACR on arenaviral combo with Roche's PD1-IL2v.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837023009248/0001558370-23-009248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837023009248/hook-20230511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer